Brava Health announced the integration of a proprietary pain validation and chronic care methodology, developed by Johns Hopkins alumni and professors, into its EMR platform to support earlier diagnostics, longitudinal..
Ruffer’s 2026 review argues that investors face a more fractured and demanding environment, making resilience, timing and disciplined positioning increasingly important...
CMC Markets has launched a single platform that combines investing and trading, a move that could broaden its client appeal and strengthen its market positioning...
Elemental Royalty announced that its common shares will start trading on the Toronto Stock Exchange on April 7, 2026, under the symbol ELE, with a concurrent voluntary delisting from the..
Drax is positioning its Yorkshire power station as a potential AI data centre hub, linking existing grid infrastructure, future power demand and longer-term carbon removal ambitions...
Volta Finance Limited reported NAV of €256.0 million as at 31 January 2026, alongside annualised cashflow generation of around 16% and a share price total return of 1.8% over the..
Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...
Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks..
The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...
Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance..
Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp..
Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical..
In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim..
Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...
Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial..
Hardman & Co highlights that Arbuthnot Banking Group delivered strong growth in deposits, funds under management and specialist lending in 2025, despite a 31% fall in pre-tax profit driven by..
Brava Health announced the integration of a proprietary pain validation and chronic care methodology, developed by Johns Hopkins alumni and professors, into its EMR platform to support earlier diagnostics, longitudinal monitoring, and more informed clinical decision-making...
Ruffer’s 2026 review argues that investors face a more fractured and demanding environment, making resilience, timing and disciplined positioning increasingly important...
CMC Markets has launched a single platform that combines investing and trading, a move that could broaden its client appeal and strengthen its market positioning...
Elemental Royalty announced that its common shares will start trading on the Toronto Stock Exchange on April 7, 2026, under the symbol ELE, with a concurrent voluntary delisting from the TSX Venture Exchange...
Drax is positioning its Yorkshire power station as a potential AI data centre hub, linking existing grid infrastructure, future power demand and longer-term carbon removal ambitions...
Volta Finance Limited reported NAV of €256.0 million as at 31 January 2026, alongside annualised cashflow generation of around 16% and a share price total return of 1.8% over the period...
Gene therapy is gaining investor attention because it offers a more direct way to treat rare genetic diseases, while also bringing important questions around access, cost and long-term evidence...
Interim results for the six months to 28 February 2026 show Baillie Gifford Japan Trust delivered positive NAV and share price returns, but lagged the benchmark, while continuing share buybacks and adding new growth holdings...
The Merchants Trust said NAV total return was 18.9% for the year ended 31 January 2026 and proposed a total dividend of 29.5p, marking its 44th consecutive annual increase...
Atalaya Mining has acquired 4.5 million Lara Exploration shares through a private placement for C$13.5 million, giving it an approximate 7.3% stake. Lara plans to use the proceeds to advance the Planalto copper-gold project in Brazil and for general corporate purposes...
Ahead of full-year results on 28 May 2026, SSE said it expects adjusted EPS of 147–152 pence for the year ended 31 March 2026. The company also reported a sharp rise in networks investment, renewables output of around 14.5 TWh and capital investment of about £3.5bn...
Smiths has completed its acquisition of DRC Heat Transfer, adding complementary thermal products and solutions to Flex-Tek and strengthening its position in growing markets such as backup power and mission-critical applications...
In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...
Firering Strategic Minerals said production at its Limeco lime project in Zambia continues to improve, with Kiln 2 now averaging more than 70 tonnes per day during its optimisation phase...
Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial launch of its CIZ1B biomarker test in North America, expansion in the UK and Europe, and ongoing clinical work with Moffitt Cancer Center...
Hardman & Co highlights that Arbuthnot Banking Group delivered strong growth in deposits, funds under management and specialist lending in 2025, despite a 31% fall in pre-tax profit driven by lower margins and softer one-off activity. The group remains well capitalised, conservatively managed and priced at a steep discount to book value...
